July 13, 2017, is the day for the review of FDA’s Oncology Drug Advisory Committee (ODAC) will review biologics license applications for biosimilars to trastuzumab (Herceptin) and bevacizumab (Avastin).
On July 13, 2017, the FDA’s Oncology Drug Advisory Committee (ODAC) will review biologics license applications (BLAs) for 2 proposed biosimilars treating cancer. During the morning session, the committee will discuss BLA 761028 for ABP 215, a proposed biosimilar to Genentech/Roche’s bevacizumab (Avastin), submitted by Amgen Inc. During the afternoon session, the committee will discuss BLA 761074 for MYL-1401O, a proposed biosimilar to Genentech Inc’s trastuzumab (Herceptin), submitted by Mylan GmbH.
This is an important day for patients with cancer, such as those with breast cancer—the most common cancer diagnosed in the United States with more than 255,000 new cases expected in 2017—as the unmet need for access to life-saving and more affordable biosimilars treating cancer continues to move towards becoming a reality.
ABP 215
ABP 215 is being developed as a biosimilar to bevacizumab, which is approved in the United States, the European Union (EU) and other countries for the treatment of patients with unresectable, locally advanced, recurrent, or metastatic non-squamous non-small cell lung cancer (NSCLC) as well as metastatic carcinoma of the colon or rectum; metastatic renal cell carcinoma; and other region-specific indications.
ABP 215 is a biosimilar candidate to bevacizumab, a recombinant immunoglobulin G1 monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits the interaction of VEGF with its receptors, VEGF receptor-1 and VEGF receptor-2, thus preventing angiogenesis necessary for the maintenance and growth of solid tumors. The BLA submission for the proposed biosimilar to Avastin includes analytical, pharmacokinetic and clinical data, as well as pharmacology and toxicology data. The phase 3 comparative efficacy, safety, and immunogenicity study, conducted in adult patients with NSCLC, confirmed no clinically meaningful difference with bevacizumab in terms of efficacy, safety and immunogenicity.
This is the first bevacizumab biosimilar application to the FDA and Amgen’s first oncology biosimilar candidate submitted for FDA approval. Amgen and Allergan are collaborating on the development and commercialization of bevacizumab as well as 3 other oncology biosimilars. Both companies are also independently developing biosimilars, and Amgen has a total of 10 biosimilars in its portfolio, one of which is FDA approved.
The expected availability of the bevacizumab biosimilar to cancer patients will be sometime after September 14, 2017, the Biosimilar User Fee Act (BsUFA) target action date set by the FDA.
MYL-1401O
MYL-1401O is being developed as a biosimilar to trastuzumab, which is approved in the United States, EU, and other countries for the treatment of patients with Human Epidermal Growth Factor Receptor 2 HER2-positive metastatic breast cancer and metastatic gastric cancer. MYL-1401O is a biosimilar candidate to trastuzumab, a monoclonal antibody that continuously blocks HER2 receptors that stimulate tumor proliferation.
The BLA submission for the proposed biosimilar to Herceptin includes a comprehensive package of analytical similarity, non-clinical and clinical data that will demonstrate the similarity of the proposed biosimilar trastuzumab to the reference product. This is the first trastuzumab biosimilar application to the FDA.
Mylan and Biocon are collaborating on the development and commercialization of trastuzumab as well as 5 other biologic products for the global marketplace. Mylan has a total of 16 biosimilar products in development and has one of the industry’s broadest biosimilars portfolios. The expected availability of the trastuzumab biosimilar to cancer patients will be sometime after September 3, 2017, the BsUFA target action date set by the FDA. There will be no legal hurdle blocking the potential US (and global) launch of its biosimilar because Mylan reached a settlement agreement with Genentech and Roche on March 13, 2017.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.